πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron UK Patents

Full USPTO pharma patent portfolio for Regeneron UK β€” grant dates, expiration, and drug cross-links.

Patents
837
Expiring ≀24m
26

Quick answer

Regeneron UK has 837 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 26 expire within 24 months β€” use filters for patent-cliff planning.

Page 9 of 18

  1. US 11019810

    Non-human animals having a humanized signal-regulatory protein gene

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11020686

    Methods for quantitating individual antibodies from a mixture

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11020495

    Humanized low affinity FCΞ³R mouse cells

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11013220

    Humanized dipeptidyl-peptidase IV (DPP4) animals

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10995146

    Methods of treating severe insulin resistance by interfering with glucagon receptor signaling

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10995150

    Methods for inhibiting atherosclerosis by administering an anti-PCSK9 antibody

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10988537

    Antibodies comprising chimeric constant domains

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10975139

    Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10973879

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10968278

    Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10954289

    Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10947310

    Fusion protein comprising apelin and an anti-APLNR antibody

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10947312

    Human antibodies to GFRΞ±3 and methods of making thereof

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10939673

    Method of using mouse having a humanized cluster of differentiation 47 gene

    Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10940211

    Human antibodies to S. aureus hemolysin A toxin

    Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10941213

    Anti-TMPRSS2 antibodies and antigen-binding fragments

    Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10941210

    Anti-PCSK9 antibodies

    Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10941208

    Anti-MUC16 antibodies

    Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10934349

    Methods for increasing lean body mass with resistance training and a GDF8 inhibitor that is an anti-GDF8 antibody

    Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10935554

    Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)

    Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10925971

    Methods of treating PRLR positive breast cancer

    Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10927435

    Compositions for the treatment of rheumatoid arthritis and methods of using same

    Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10905784

    Radiolabeled anti-LAG3 antibodies for immuno-PET imaging

    Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10888601

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10881086

    Genetically modified mouse whose genome comprises a humanized CD274 gene

    Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10875911

    High affinity human antibodies to human angiopoietin-2

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10863729

    Rodents having a humanized TMPRSS gene

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10865236

    Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10857205

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10857231

    Formulations of VEG antagonist fusion proteins and method of manufacturing them

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10851158

    Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10844137

    Anti-CTLA-4 antibodies and uses thereof

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10829544

    Human antibodies to Ebola virus glycoprotein

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10828345

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10815305

    Methods of treating inflammatory conditions

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10806780

    Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

    Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10793624

    Human antibodies to Bet v 1 and methods of use thereof

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10785966

    Humanized M-CSF mice

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10787647

    HSD17B13 variants and uses thereof

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10787501

    Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10785968

    Genetically modified non-human animals and methods of use thereof

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10772972

    Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10772956

    Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10774128

    IL-33 antagonists and uses thereof

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10765762

    Humanized model of kidney and liver disorders

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10752702

    Anti-TIE2 antibodies and uses thereof

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10752701

    Stabilized formulations containing anti-PCSK9 antibodies

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10752690

    Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron UK have?

837 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron UK patents expire?

26 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.